IDEAYA Biosciences will use ESMO 2026 to expand the clinical case for darovasertib across three uveal melanoma settings and test the durability of IDE849 responses in small-cell lung cancer.
Servier is buying sevasemten before pivotal muscular dystrophy data. The deal gives Edgewise cash and investors a sharper cardiology story.
IDEAYA Biosciences will report OptimUM-02 topline data on April 13. Read why this uveal melanoma trial could shift the treatment landscape.
Servier plans a $2.5B acquisition of Day One Biopharmaceuticals to expand its rare oncology pipeline. Discover what the deal means for pediatric glioma.